CEO Elizabeth Barrett highlighted the progress of the ZUSDURI launch and noted, "The preliminary demand revenue for October is more than double the previous 3 months, demonstrating increased usage and ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback